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Background: Colorectal cancer (CRC) is among the five most frequent causes for cancer-related deaths in Europe.
One of the most important tumor-associated antigens for CRC is carcinoembryonic antigen-related cell adhesion
molecule 5 (CEACAM5), which is involved in cell adhesion, migration, anoikis, tumor invasion and metastasis. Its family
member CEACAM6 is also upregulated in adenomas and carcinomas of the colon and an independent predictor of
poor survival. Previous studies have reported a link between upregulation of CEACAM5 and interleukin-6 (IL-6). IL-6
plays an important role in CRC progression, and signaling is mediated via two pathways (classic and trans-signaling).
However, this link could not be confirmed by other studies, and the role of IL-6 trans-signaling in the CEACAM5
upregulation has not been elucidated. Moreover, the impact of IL-6 on the expression of CEACAM6 has not yet
been examined.
Methods: The expression of IL-6, IL-6 receptor (IL-6R), glycoprotein (gp) 130, CEACAM5 and CEACAM6 was analyzed by
RT-PCR, Western blot, flow cytometry or qPCR. Colon cell lines were incubated with IL-6 or Hyper-IL-6 (mediating IL-6
trans-signaling), and subsequently, the expression of CEACAMs was determined by qPCR or Western blot. FLLL31, an
inhibitor of the phosphorylation of signal transducer and activator of transcription-3 (STAT3), was used to determine
the role of STAT3 phosphorylation.
Results: We confirmed that colon carcinoma cell lines express IL-6 and IL-6R. We observed only a weak upregulation
of CEACAM5 and CEACAM6 by classic IL-6 signaling, but a strong increase by IL-6 trans-signaling. This upregulation
depended on the phosphorylation of STAT3.
Conclusions: Our data show the upregulation of the tumor-associated antigens CEACAM5/6 by trans-signaling of the
pro-inflammatory cytokine IL-6. This mechanism may contribute to the tumor-promoting role of IL-6 and could
therefore be a target for therapeutic intervention in particular by specific inhibitors such as sgp130Fc.
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CRC is still one of the leading causes of cancer deaths in
Europe. According to calculations for the year 2014, it
ranks second in men and third in women [1]. Several
risk factors exist, including smoking, alcohol consump-
tion, diabetes and inflammation [2, 3]. The link between
inflammation and tumorigenesis is exemplified by patients
with colitis-associated cancer (CAC). These are CRC
patients that have previously suffered from inflammatory
bowel disease (IBD). It is well-known that IBD patients
have a higher risk of developing CAC/CRC [4, 5].
One of the key cytokines in IBD as well as in CRC is
IL-6 [6]. IL-6 is a pleiotropic cytokine involved in vari-
ous processes of innate and adaptive immunity [7, 8]. In
the classic IL-6 signaling pathway, IL-6 binds to the
membrane-bound IL-6R, which subsequently transmits
the signal via the recruitment and homodimerization
of two gp130 subunits. Consequently, an intracellular
cascade is activated involving STAT3, mitogen-activated
protein kinase (MAPK) and phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) activation [9]. Whereas
gp130 is ubiquitously expressed, IL-6R expression is
restricted to only a few cell types, such as hepatocytes and
certain leukocytes. However, a soluble form of IL-6R (sIL-
6R) is generated by protease-mediated receptor shedding
from the membrane or by alternative splicing. In contrast
to some other soluble receptors, the sIL-6R does not act
as an antagonist. Instead, it binds to IL-6 and trans-
activates cells that only express gp130. This process was
termed trans-signaling [9]. It is selectively inhibited by a
naturally occuring soluble form of gp130 (sgp130). This
knowledge was used to generate a potent and selective
inhibitor of trans-signaling by fusing the sgp130 protein to
the Fc part of a human IgG1 antibody. The resulting
fusion protein is called sgp130Fc [9] and the optimized
variant FE 999301 has already entered clinical develop-
ment for the treatment of inflammatory bowel disease.
Several studies demonstrated a significant role of IL-6
in IBD as well as in CRC. These studies were recently
reviewed by Waldner and Neurath, who concluded that
IL-6 is the "master regulator of intestinal disease" [6].
Interestingly, in most studies, the pro-inflammatory and
tumor-promoting activity of IL-6 was mediated via IL-6
trans-signaling [6, 10].
A causal link between IL-6 and CEACAM5 is revealed
by significant association of serum levels of IL-6 with
high serum levels of CEACAM5 [11, 12]. CEACAM5
(also called carcinoembryonic antigen, CEA) is one of
the best-known tumor-associated antigens for CRC
[13–15]. It is expressed in normal mucosal cells of
the colon, but overexpressed in adenocarcinomas of the
colon. In addition, its serum levels are elevated in CRC
patients [15]. CEACAM5 is an adhesion molecule that
was shown to be involved in cell adhesion, migration,anoikis, tumor invasion and metastasis [16, 17]. Further-
more, it activates inhibitory CEACAM1 signaling in natural
killer cells (NK cells) and thereby blocks the cytotoxicity of
NK cells [17]. CEACAM6, another family member of the
carcinoembryonic antigen family, is already upregulated in
benign precursor lesions like hyperplastic colorectal polyps
and early adenomas [18]. Moreover, CEACAM6 is an
independent predictor of poor survival for CRC pa-
tients [19] and is involved in tissue architecture and
colonocyte differentiation [20].
IL-6 was previously shown to increase the expression
of CEACAM5 on some CRC cells [21, 22]. However, this
relationship was not observed for all CRC cell lines, and
another study only found a very small and not significant
stimulatory effect of IL-6 on the CEACAM5 expression
[23]. To our knowledge, no study has yet examined the
relationship between IL-6 trans-signaling and CEA-
CAM5 and CEACAM6. Thus, the aim of this study was
to systematically analyze the impact of IL-6 classic and
trans-signaling on the expression of CEACAM5 and
CEACAM6 in colorectal cancer cells.
Methods
Cell culture and proteins
The human colorectal adenocarcinoma cell lines HT29
(called HT29p for ’parental’ cells to distinguish it from
other HT29 derivatives in our laboratory) and SW480 were
obtained from the American Type Culture Collection
(ATCC). HT29c cells had been generated in our laboratory
by repeated injection of HT29 cells into the portal venous
system of nude rats, subsequent isolation from liver metas-
tases and reculturing in vitro [24, 25]. Colo357 cells, de-
rived from a metastasis of a pancreatic adenocarcinoma,
were a kind gift of Dr. R. Morgan (Denver, CO) [26]. These
cells were routinely cultured in Roswell Park Memorial
Institute (RPMI)-1640 medium (Gibco/Life Technologies,
Darmstadt, Germany) supplemented with 10 % fetal bovine
serum (FBS, PAN-Biotech, Aidenbach, Germany), 1 mM
sodium pyruvate (Gibco) and 2 mM glutaMAX (Gibco).
The human colorectal adenocarcinoma cell line Caco-2
was obtained from ATCC. It was cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco) supplemented
with 10 % FBS, 1 mM sodium pyruvate and 2 mM gluta-
MAX. The normal mucosa-derived colon cell lines CSC1
[27] and NCM460 [28] were a kind gift of Dr. Mary Pat
Moyer (San Antonio, TX, USA). These cell lines were
maintained in M3 Base cell culture medium complete
(M300A-500, Incell, San Antonio, TX, USA) with 10 %
FBS. Ba/F3-gp130/IL-6R cells are Ba/F3 pre-B cells lacking
endogenous gp130, which had been stably transfected
with IL-6R and gp130 as a model system for IL-6 signaling
[29, 30]. They were cultured in DMEM high glucose
medium (Gibco) supplemented with 10 % FBS, 1 mM
sodium pyruvate, 2 mM glutaMAX and 1 ng/ml IL-6.
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sIL-6R mimicking the IL-6 trans-signaling complex –
were produced by the group of Prof. Stefan Rose-
John as previously described [31, 32]. All cells were
maintained at 37 °C in a humid atmosphere with 5 %
CO2 and routinely checked for mycoplasma contam-
ination with the MycoTrace kit (PAA/GE Healthcare,
Cölbe, Germany).RNA isolation and cDNA synthesis
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen,
Hilden, Germany). RNA concentration was measured in a
Nanodrop spectrophotometer (Thermo Fisher Scientific,
Dreieich, Germany) and quality-checked on a 1 % agarose
gel. 2 μg of RNA were reverse-transcribed into cDNA
using the Maxima First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific).Reverse transcriptase polymerase chain reaction (RT-PCR)
PCR was performed using the Dream Taq Green Polymer-
ase (Thermo Fisher Scientific). The primer sequences are
depicted in Table 1, and the following conditions were used:
initial denaturation: 95 °C, 2 min; denaturation: 95 °C, 30 s;
annealing: 60 °C, 30 s; extension: 72 °C, 1 min (40 cycles);
final extension: 72 °C, 10 min. The PCR product was ana-
lyzed by agarose gel electrophoresis on a 2 % agarose gel.Quantitative real-time polymerase chain reaction (qPCR)
cDNA was diluted 100-fold in nuclease-free water. 2 μl
of diluted cDNA were used in a 20 μl reaction with
FastSybr Green mastermix (Applied Biosystems/Life
Technologies). The primer sequences are depicted in
Table 2, and the following conditions were used: initial
denaturation: 95 °C, 20 s; denaturation: 95 °C, 3 s;
annealing/extension: 60 °C, 30 s (usually 40 cycles).
Specificity of the product was verified by melt curve










RPL22 ribosomal protein L22Phorbol-12-myristate-13-acetate (PMA) stimulation and
enzyme-linked immunosorbent assays (ELISAs)
For PMA stimulation, HT29p cells were seeded in a
96-well plate. On the next day, the medium was
changed to remove non-adherent or dead cells. After
72 h, the supernatants were collected to measure the
baseline (unstimulated) sIL-6R production of the cells
(data not shown). Subsequently, the medium was
changed, and the cells were stimulated for 2 h at room
temperature (RT) with medium containing either 100 nM
PMA (Calbiochem/Merck, Darmstadt, Germany) dis-
solved in dimethyl sulfoxide (DMSO) or 0.5 % DMSO as
solvent control in triplicate wells. Supernatants from the
triplicate wells were harvested and centrifuged for 15 min
at 16,000 x g and 4 °C to remove cells and cellular debris.
The purified supernatants were stored at −80 °C until
ELISA analysis. sIL-6R concentrations were measured
using ELISA kits (R&D Duoset, R&D Systems, Wiesbaden,
Germany) according to the manufacturer’s instructions.
Analysis of STAT3 phosphorylation and CEACAM
expression by Western blotting
To analyze the phosphorylation of STAT3 and CEA-
CAM5/6, HT29p cells were seeded in 6-well plates. After
48 h, the medium was replaced by serum-free medium.
The next morning, cells were stimulated with different
concentrations of IL-6 or Hyper-IL-6, a fusion protein of
IL-6 and sIL-6R mimicking the IL-6 trans-signaling
complex (see above). After 15 min (STAT3) or 48 h
(CEACAM5/6), the cells were lysed with radioimmu-
noprecipitation assay (RIPA) buffer and stored at −20 °C
until analysis for STAT3 phosphorylation in Western blots.
For Western blots, the lysates were thawed on ice,
sonicated and centrifuged (13,000 rpm, 15 min, 4 °C) to
remove cellular debris. Protein concentration was
determined with the DC assay (Bio-Rad Laboratories,
Munich, Germany). Equal amounts of protein were
loaded onto a 4–20 % tris-glycine gel (Life Technologies)
and separated by SDS-PAGE. Proteins were blotted on a
PVDF membrane (Immobilon-FL; Millipore/Merck,Amplicon [bp] (mRNA/genomic) Reference
280/not amplified [54]







Table 2 Primers used for qPCR
Name Sequence 5’-3’ Amplicon [bp] (mRNA/genomic) Reference
hu_CEA_For CTTTATCGCCAAAATCACGC 138/6195 http://primerdepot.nci.nih.gov
hu_CEA_Rev CCAGCTGAGAGACCAGGAGA 138/6195 http://primerdepot.nci.nih.gov
hu_CEACAM6_For1 GCATGTCCCCTGGAAGGA 179/1076 [57]
hu_CEACAM6_Rev1 CGCCTTTGTACCAGCTGTAA 179/1076 [57]
hu_RPL22_For TCGCTCACCTCCCTTTCTAA 250/6652 [56]
hu_RPL22_Rev TCACGGTGATCTTGCTCTTG 250/6652 [56]
hu_PPIC_For GGAAAAGTCATTGATGGGATG 127/1907 sequence from Eva Simon, Kiel
hu_PPIC_Rev CAAAAGGCGTTTTCACGTCTA 127/1907 sequence from Eva Simon, Kiel
hu_SDHA_For ATTTGGTGGACAGAGCCTCA 126/not amplified sequence from Eva Simon, Kiel
hu_SDHA_Rev CTGGTATCATATCGCAGAGACCT 126/not amplified sequence from Eva Simon, Kiel
RPL22 ribosomal protein L22, PPIC peptidylprolyl isomerase C, SDHA succinate dehydrogenase complex, subunit A, flavoprotein
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serum albumin for 1 h at RT and incubated with the
primary antibody overnight at 4 °C. Secondary antibody
incubation was performed for 1 h at RT. All washes were
performed with TBS supplemented with 0.01 % Tween-20.
Blots were dried with methanol and scanned in an
Odyssey imager (LI-COR, Bad Homburg, Germany).
Alternatively, horseradish peroxidase (HRP)-coupled
secondary antibodies were used. After incubation, these
membranes were incubated with a substrate for electro-
chemiluminescence (ECL), and readout was performed
using films (Amersham Hyperfilm ECL, both from GE
Healthcare, Munich, Germany) and an Agfa Curix 60
developing machine (Agfa, Mortsel, Belgium). The
following antibodies were used: P-STAT3 (#9131, Cell
Signaling Technology/New England Biolabs, Schwalbach,
Germany), STAT3 (#9139, Cell Signaling Technology),
β-actin (ab6276, Abcam, Cambridge, UK), goat-anti-
mouse-IRDye680 (LI-COR), goat-anti-rabbit-IRDye800CW
(LI-COR), CEACAM5 (T84.66, kindly provided by Stefanie
Nittka, Mannheim, Germany), CEACAM6 (AM02001PU-
N, Acris, Herford, Germany), goat-anti-rabbit IgG-HRP
(#7074, Cell Signaling) and horse-anti-mouse IgG-HRP
(#7076, Cell Signaling).
CEACAM analysis by flow cytometry
For the analysis of CEACAM molecules by flow cytometry,
cells were harvested after Accutase treatment (GE Health-
care, Munich, Germany). Subsequently, all steps were
performed on ice. Cells were washed with FACS buffer
(PBS with 2 % human serum, 2 mM EDTA and 0.02 %
sodium azide), blocked with FACS buffer for 15 min and
stained with primary antibodies diluted in FACS buffer
(30 min on ice). Subsequently, they were washed three
times with FACS buffer and incubated with the
fluorochrome-coupled secondary antibody. After washing,
the cells were incubated with FACS buffer containing
7AAD (BD Bioscience, Franklin Lakes, NJ, USA).Afterwards, the cells were measured in a FACScalibur
(BD). Weasel software v3.0 (chromocyte, Sheffield, UK)
was used for data analysis. Dead cells were excluded by
gating for the 7AAD-negative cells, as dead cells were
previously shown to be false positive for CEACAM5/6.
The following antibodies were used: CEACAM5 (C1P83,
produced by our group as previously described [33, 34]),
CEACAM6 (AM02001PU-N, Acris, Herford, Germany),
mouse IgG1-isotype control (X0931, Dako, Glostrup,
Denmark) and anti-mouse-IgG-Alexa488 (Invitrogen/Life
Technologies, Darmstadt, Germany).
Ethics statement
Our study is in compliance with the Helsinki Declaration.
We did not perform a clinical trial or used any materials
from clinical specimens and therefore, no consent of
patients was necessary. Only the cell lines used in this
work were obtained from the sources indicated in the
“Cell culture and protein” section.
Results
Colon cell lines express molecules mediating IL-6 signaling
To understand the impact of IL-6 on colon cells, we first
analyzed by reverse transcription polymerase chain reac-
tion (RT-PCR) whether mucosa-derived colon cell lines
(CSC1, NCM460) and colorectal cancer cell lines (Caco-2,
HT29p, HT29c, SW480) express key components of the
IL-6 signaling pathway. The mucosa-derived cell lines
were originally isolated from histologically normal colonic
margins from patients undergoing resection for colon
adenocarcinomas and represent the disease in its early
stages of transformation [27, 35]. Most cell lines expressed
IL-6 mRNA. However, the level among the cell lines
varied, and the parental HT29 cell line (HT29p) did not
show any IL-6 expression (Fig. 1a). In contrast, the
cell line HT29c, which was derived from HT29p cells
using a successive intrahepatic selection procedure in














































Fig. 1 Colon cells express IL-6, IL-6R and gp130. a, RNA from different colorectal cancer cells (Caco-2, HT29p, HT29c, SW480) and normal
mucosa-derived colon cells (CSC1, NCM460) was extracted, reverse-transcribed into cDNA and analyzed for the expression of IL-6, IL-6R and gp130. The
pancreatic cell line Colo357 served as a positive control. Ribosomal protein L22 (RPL22) was used as a reference gene to monitor equal transcription of
cDNA. b, HT29p cells were seeded in 6-well plates. After 72 h, the medium was replaced by medium containing either the solvent dimethyl sulfoxide
(DMSO) or phorbol-12-myristate-13-acetate (PMA) in DMSO. Supernatants were collected after 2 h, and the sIL-6R concentration was determined by
ELISA. Ba/F3-gp130-mIL-6R cells were used as a positive control. n.d. not detected
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co-receptor gp130.
However, we did not detect the IL-6R on the surface
of colorectal cancer cells by flow cytometry (data not
shown). Therefore, we assumed that either the expres-
sion level was low or that the receptor was shed. IL-6R
is mainly shed by ADAM17, which is strongly activated
by phorbol-12-myristate-13-acetate (PMA) [36]. Stimu-
lation of HT29p cells with PMA led to an increase of
the sIL-6R concentration in the supernatant (Fig. 1b),
demonstrating that colorectal cancer cells express the
IL-6R protein on their membrane, and that it can be
shed from the surface.Fig. 2 Most colon cell lines express mRNA of CEACAM5 and CEACAM6. a,
SW480) or normal mucosa-derived colon cell lines (CSC1, NCM460) were se
by qPCR for the expression of CEACAM5 and CEACAM6. PPIC and RPL22 w
(not shown)CEACAM5 and CEACAM6 are expressed in most colon
cell lines
Before we analyzed the relationship between IL-6 and
CEACAMs, we examined the expression of CEACAM5
and CEACAM6 in the normal mucosa-derived and colo-
rectal cancer cell lines. Most of these cell lines expressed
CEACAM5 as well as CEACAM6. However, the level
varied between different cell lines. On the mRNA level,
HT29p and NCM460 cells showed the highest expres-
sion of CEACAM5 (Fig. 2). HT29p also had the highest
mRNA level of CEACAM6. Interestingly, the variant
HT29c showed a much lower expression of CEACAM5
and CEACAM6 than HT29p. The cell line Caco-2150,000 or 300,000 (b) colorectal cancer cells (Caco-2, HT29p, HT29c,
eded in 6-well plates. After 48 h, the RNA was extracted and analyzed
ere used as reference genes. SW480 cells did not show any expression
Fig. 3 Most colon cell lines express CEACAM5 and CEACAM6 proteins on their surface. a, The CEACAM5/6 expression of different colorectal
cancer cell lines (HT29p, HT29c) and normal mucosa-derived colon cell lines (CSC1, NCM460) was analyzed by flow cytometry using specific
antibodies (grey) or an unspecific isotype control (white). The amount of positive cells (b) as well as the difference in the mean fluorescence
intensity (dMean) between the specific staining and the isotype control (c) was analyzed
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CAM6 with higher confluency (Fig. 2). SW480 cells did
not express any CEACAM5/6 (data not shown).
On the protein level, we analyzed the CEACAM5/6
surface expression by flow cytometry (Fig. 3). In a given
cell population, only a fraction of cells was positive for
CEACAM5 and CEACAM6. Similar to our findings onFig. 4 Hyper-IL-6 strongly activates STAT3 and increases the expression of
serum-starved overnight and stimulated with different concentrations of IL
analyzed for STAT3 phosphorylation in Western blots by ECL. b, HT29p cell
with IL-6 (100 ng/ml) or Hyper-IL-6 (15 ng/ml). After 6 or 24 h, the RNA wa
CEACAM6. PPIC and SDHA were used as reference genes. Three independe
plates, serum-starved overnight and treated with IL-6 (100 ng/ml; “I”) or Hy
or 48 h (CEACAM expression), cells were lysed and the lysates analyzed for th
blots and scanned in the Odyssey near-infrared imaging system. β-actin was
shown in different intensitiesthe mRNA level, HT29p cells had the highest surface pro-
tein expression level (represented by the difference in the
mean fluorescence intensity between isotype control-
stained and CEACAM5/6-stained cells), as well as the
highest percentage of positive cells (Fig. 3). NCM460 cells
showed a similar amount of positive cells, but the expression
level was lower than in HT29p cells. Again, HT29c cellsCEACAM5 and CEACAM6. a, HT29p cells were seeded in 6-well plates,
-6 or Hyper-IL-6. After 15 min, the cells were lysed and the lysates
s were seeded in 6-well plates, serum-starved overnight and stimulated
s isolated and analyzed by qPCR for the expression of CEACAM5 and
nt experiments are shown. c, Different cell lines were seeded in 6-well
per-IL-6 (15 ng/ml; “H”). After 15 min (to examine STAT3 phosphorylation)
e phosphorylation of STAT3 and the expression of CEACAM in Western
used to monitor equal protein loading. For CEACAM5/6, the blots are
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and SW480 did not show any surface expression.
IL-6 trans-signaling upregulates the expression of
CEACAM5 and CEACAM6 in colon cancer cells
To study the effect of IL-6 classic and trans-signaling,
cells were stimulated either with IL-6 or Hyper-IL-6
(consisting of human IL-6 linked by a flexible peptide
chain to the soluble form of the IL-6 receptor) at differ-
ent concentrations. For this preliminary experiment, the
cell line HT29p was chosen, because it did not show an
endogenous IL-6 expression (Fig. 1a). As one of the
earliest steps in the IL-6 signaling cascade, we analyzed
the phosphorylation of STAT3. While IL-6 only weakly
activated STAT3, Hyper-IL-6 led to a strong phosphoryl-
ation even at low concentrations (Fig. 4a). This suggests
that HT29p cells express IL-6R only in small amounts
and are not very responsive to IL-6.
To answer the question whether IL-6 signaling leads
to an upregulation of the CEACAM5/6 expression, we
treated HT29p cells with IL-6 (100 ng/ml) or Hyper-IL-6
(15 ng/ml) and analyzed the CEACAM5/6 expression on
the mRNA level after 6 and 24 h. After 6 h, only slight
changes were observed, but after 24 h, expression of CEA-
CAM5 and CEACAM6 was clearly increased by Hyper-
IL-6 stimulation (Fig. 4b). In contrast, IL-6 only led to
slight changes in the CEACAM5/6 expression (Fig. 4b).
We confirmed this finding at the protein level in the
two normal mucosa-derived cell lines (CSC1, NCM460)
and two representative colorectal cancer cell lines which
express CEACAM5 and CEACAM6 (HT29p, HT29c)
(Fig. 4c). STAT3 was strongly phosphorylated by Hyper-
IL-6 in all of these cell lines. Stimulation with IL-6 led
to a much weaker STAT3 phosphorylation, although its
concentration was much higher than that of Hyper-IL-6.
Consequently, the CEACAM expression was not as
strongly increased as with Hyper-IL-6. The cell lineFig. 5 Inhibition of STAT3 phosphorylation prevents the Hyper-IL-6-mediated
plates, serum-starved overnight and pre-treated with FLLL31 (5 μM) for 2 h. S
Hyper-IL-6 (15 ng/ml). After 15 min, cells were lysed and the lysates analyzed
isolated and analyzed by qPCR for the expression of CEACAM5 and CEACAM6SW480 did not express any detectable CEACAM5 or
CEACAM6. This also did not change after treatment
with IL-6 or Hyper-IL-6, indicating that CEACAM ex-
pression is not inducible by IL-6 de novo, but is typically
stimulated by IL-6 trans-signaling (Fig. 4c). While the
relationship between IL-6 and CEACAM5 expression
was not clear in the literature, our data suggest that IL-6
leads to a small increase in the expression of CEACAM5
and CEACAM6, but that this increase is much stronger
when IL-6 trans-signaling occurs. This may be due to
the low IL-6R expression. Furthermore, we show here
for the first time that CEACAM6 is upregulated by IL-6
trans-signaling.The phosphorylation of STAT3 is necessary for the
Hyper-IL-6-mediated increase in CEACAM5/6
To analyze whether the Hyper-IL-6-mediated increase in
CEACAM5/6 expression depends on the phosphoryl-
ation of STAT3, HT29p cells were pre-treated with
FLLL31, a small molecule STAT3 inhibitor derived from
curcumin [37]. Subsequently, the cells were stimulated
either with normal serum-free medium or with Hyper-
IL-6. FLLL31 clearly inhibited the Hyper-IL-6-induced
phosphorylation of STAT3 (Fig. 5a) and the increase in
CEACAM5/6 expression (Fig. 5b).IL-6 trans-signaling stabilizes hypoxia-inducible factor 1α
(HIF-1α), and chemical stabilization of HIF-1α upregulates
CEACAM5/6
IL-6 was shown to increase the expression of HIF-1α
at the protein synthesis level [38]. HIF-1α, in turn,
was described to upregulate CEACAM5 and CEA-
CAM6 [39, 40]. Therefore, we tested whether the ob-
served (Hyper-)IL-6-mediated CEACAM5/6 increase
could be due to an increased HIF-1α level.increase of CEACAM expression. a, HT29p cells were seeded in 6-well
ubsequently, cells were treated with serum-free medium with or without
for the phosphorylation of STAT3 in Western blots. b, After 24 h, RNA was
. PPIC and RPL22 were used as reference genes
Fig. 6 (See legend on next page.)
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Fig. 6 Hyper-IL-6 increases the expression of HIF-1α on the protein level. a, HT29p cells were treated with Hyper-IL-6 (15 ng/ml) or with 100 μM
of deferoxamine mesylate (DFO) as a positive control. Cells were lysed at the indicated time points and analyzed by Western blotting for the
expression of HIF-1α. b, HT29p cells were treated with Hyper-IL-6 (15 ng/ml). After 6 or 24 h, RNA was extracted and analyzed by qPCR for the
expression of HIF-1α. The expression of CEACAM6 was used as a positive control. Three independent experiments are shown. c, HT29p cells were
seeded in 6-well plates. Cells were serum-starved and subsequently stimulated with DFO (100 μM) or with Hyper-IL-6 (15 ng/ml). After 24 h, RNA
was extracted and analyzed by qPCR for the expression of CA9, VEGF, CEACAM5 and CEACAM6. Three independent experiments are shown
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Hyper-IL-6 indeed increased HIF-1α on the protein level
after 6 h of incubation. At later time points, this differ-
ence decreased (Fig. 6a). On the mRNA level, we did not
detect a significant upregulation of HIF-1α mRNA
(Fig. 6b). HIF-1α is chemically stabilized by the iron che-
lator deferoxamine mesylate (DFO). DFO inhibits prolyl
hydroxylases, which degrade HIF-1α [41]. We used DFO
as a control to confirm that HIF-1α leads to an up-
regulation of CEACAMs. Treatment of HT29p cells
with DFO led to a clear upregulation of CEACAM5
as well as of CEACAM6 (Fig. 6c). The classic HIF-1α
target genes CA9 and VEGF were used as positive
controls. However, they were only upregulated by
DFO but not by Hyper-IL-6, although Hyper-IL-6 in-
creased the HIF-1α protein level in these cells. In
summary, these data support the notion that HIF-1α
plays a role in the Hyper-IL-6-induced CEACAM5/6
upregulation, but further studies are necessary to
understand the complex mechanism of regulation.
Discussion
In this study, we show that IL-6 trans-signaling
significantly upregulates the expression of CEACAM5
and CEACAM6 in CRC cells. IL-6 trans-signaling is
known to be important for the development of CRC
[6]. We show that some CRC cells constitutively
express IL-6, whereas all of the tested cell lines ex-
press IL-6R and gp130 on the mRNA level. However,
cells only weakly responded to stimulation with IL-6.
In comparison, IL-6 trans-signaling (induced by
Hyper-IL-6 mimicking the IL-6/sIL-6R complex)
strongly phosphorylated STAT3 and led to a signifi-
cant increase in CEACAM5 and CEACAM6 expres-
sion. Interestingly, cell lines originally derived from
normal mucosa [28] also expressed IL-6, IL-6R and
gp130. This is consistent with other studies, demon-
strating expression of IL-6 and mIL-6R in intestinal
epithelial cells [42].
IL-6 classic signaling weakly phosphorylated STAT3 and
increased the expression of CEACAM5 and CEACAM6
in different colon cell lines. In comparison, IL-6 trans-
signaling had a much stronger effect. This may be due to
a low IL-6R expression on the cell surface. The differential
IL-6R expression could also be the explanation why someprevious studies described an effect of IL-6 on the
CEACAM expression [21, 22] while others did not
[23]. Accordingly, we also observed a STAT3 phosphoryl-
ation and a CEACAM5/6 upregulation by classic signaling
in the pancreatic cell line Colo357, which obviously
expressed sufficient amounts of IL-6R (Additional file 1:
Figure S1).
In HT29p cells, the observed influence of IL-6 trans-
signaling on the CEACAM expression depended on the
phosphorylation of STAT3, as an inhibitor of the STAT3
phosphorylation blocked the Hyper-IL-6-mediated CEA-
CAM increase. Moreover, Hyper-IL-6 led to an increase
in HIF-1α levels. Interestingly, this increase was only
observed on the protein level but not on mRNA level, an
effect previously described for IL-6. Briggs showed in his
doctoral thesis that IL-6 increases the rate of HIF-1α
synthesis (translation) rather than the rate of transcription
[43], and STAT3 was shown to inhibit the degradation of
HIF-1α [44]. Increased translation seems to be a common
mechanism for HIF-1α increase after stimulation with
growth/oncogenic stimuli [44–46].
Stabilization of HIF-1α by the hypoxia mimetic
deferoxamine mesylate (DFO) led to an upregulation
of CEACAM5 and CEACAM6. This suggested that
HIF-1α might be involved in the Hyper-IL-6-mediated
CEACAM5/6 upregulation. Moreover, STAT3 and
HIF-1α had previously been shown to interact in
transcriptional complexes to regulate the expression
of HIF-1α target genes [47–50]. However, the classical
HIF-1α target genes CA9 and VEGF were not upreg-
ulated by Hyper-IL-6 in our settings. Therefore,
further studies are necessary to elucidate the detailed
mechanism of transcriptional regulation of CEACAM5
and CEACAM6.Conclusions
In summary, we show in this study that IL-6 trans-
signaling increases the expression of CEACAM5 and
CEACAM6 in colon cells. This may be important for
tumorigenesis, as CEACAM5 and CEACAM6 are in-
volved in adhesion, migration, invasion and metastasis
[17]. This study provides further support for inhibiting
IL-6 trans-signaling as a clinical therapeutic strategy for
colorectal cancer [51–53].
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Additional file 1: Figure S1. IL-6 influences the expression of CEACAM5
and CEACAM6 in the pancreatic cancer cell line Colo357. Colo357 cells were
treated with IL-6 (100 ng/ml) in serum-free medium or with the anti-IL-6R-
antibody tocilizumab (10 or 100 μg/ml) in serum-containing medium to
block endogenous IL-6 signaling for 24 h. RNA was isolated and qPCR
performed to analyze the expression of CEACAM5/6. (PDF 95 kb)
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